In this online program, faculty discuss how to leverage 10 of the emerging and most clinically important biomarkers to optimize patient care across multiple tumor types, from solid tumors to hematologic malignancies.
Learn about biomarkers agnostic to tumor type as well as an in-depth look at case studies in non-small-cell lung cancer, acute myeloid leukemia, and chronic lymphocytic leukemia for examples of personalized medicine in 2018.
Watch this CME/CE-certified Webcast of a dynamic CCO symposium at ASCO 2018 to review the ten most clinically relevant biomarkers in oncology with program chair John L. Marshall, MD, and experts Todd M. Bauer, MD; Hagop M. Kantarjian, MD; Edward S. Kim, MD, FACP; and Andrew D. Zelenetz, MD, PhD.
In this downloadable slideset, John L. Marshall, MD, examines key oncology biomarkers for immune checkpoint inhibition and DNA repair, MSI/MMR, PD-L1, and BRCA1/2.
In this downloadable slideset, Todd M. Bauer, MD, discusses the rationale for targeting tumor agnostic genetic aberrations in patients with cancer, including FGFR, RET, and TRK.
In this downloadable slideset, Edward S. Kim, MD, FACP, explains how various biomarkers can be used to guide treatment of patients with lung cancer, including EGFR, ALK, ROS-1, BRAF, and PD-L1.
In this downloadable slideset, Hagop M. Kantarjian, MD, discusses the use of biomarkers to guide treatment of patients with acute myeloid leukemia, including IDH, FLT3, and CD33/CD133.
In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, examines and discusses the use of del(17p)/TP53 mutations to guide treatment of patients with chronic lymphocytic leukemia.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.